MC4R Agonist
Melanocortin-4 Receptor Agonist Peptide
Synthetic peptides that selectively activate MC4R to reduce appetite and promote weight loss. Setmelanotide is FDA-approved for rare genetic obesity conditions.
Mechanism of Action
MC4R agonists activate melanocortin-4 receptors in the hypothalamus, reducing appetite and increasing energy expenditure. MC4R is the primary melanocortin receptor regulating body weight.
Health Claims & Evidence
Reduces appetite and promotes weight loss
Treatment for genetic obesity (MC4R pathway defects)
Increases energy expenditure
Short-Term Effects
Appetite reduction, weight loss.
Long-Term Effects
Sustained weight loss in MC4R pathway deficiency.
Side Effects
Hyperpigmentation, nausea, injection site reactions, spontaneous erections.
Contraindications
Not for common obesity without MC4R pathway defect.
This profile is provided for educational research only. It is not a treatment recommendation or dosing guide. Human evidence, safety information and regulatory status vary by substance. Verify primary sources and consult a qualified healthcare professional for medical decisions.
Research Papers
Setmelanotide in genetic obesity
Clément et al. · New England Journal of Medicine · 2020
Educational research only. This profile is not a treatment recommendation or dosing guide. Human evidence, safety information and regulatory status vary by substance. Consult a qualified healthcare professional for medical decisions.
Related Peptides
Explore the research further
Our AI Research Advisor can help you explore the evidence on MC4R Agonist and related peptides, and prepare an educational research summary.
Explore Research